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Abstract
In the last decade, adverse outcome pathways have been introduced in the fields of toxicology and risk assessment of chemi-
cals as pragmatic tools with broad application potential. While their use in the pharmaceutical and cosmetics sectors has 
been well documented, their application in the food area remains largely unexplored. In this respect, an expert group of the 
International Life Sciences Institute Europe has recently explored the use of adverse outcome pathways in the safety evalua-
tion of food additives. A key activity was the organization of a workshop, gathering delegates from the regulatory, industrial 
and academic areas, to discuss the potentials and challenges related to the application of adverse outcome pathways in the 
safety assessment of food additives. The present paper describes the outcome of this workshop followed by a number of 
critical considerations and perspectives defined by the International Life Sciences Institute Europe expert group.
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Abbreviations
3Rs  Replacement, reduction and refinement
AOP(s)  Adverse outcome pathway(s)
EFSA  European Food Safety Authority
ILSI  International Life Sciences Institute
KE(s)  Key event(s)
MIE(s)  Molecular initiating event(s)
OECD  Organization for Economic Cooperation and 
Development
PBK  Physiologically-based kinetic
QIVIVE  Quantitative in vitro-to-in vivo extrapolation
US EPA  United States Environmental Protection 
Agency
Introduction
Toxicology, and hence chemical safety evaluation practice, 
have drastically changed over the past few decades. In fact, 
this area is still transitioning from classical toxicology, 
focusing on measuring apical endpoints of toxicity in animal 
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models, to animal-free and more human-relevant toxicology, 
relying on mechanistic information. This paradigm shift has 
been facilitated by the introduction of the concept of adverse 
outcome pathways (AOPs) (Ankley et al. 2010), which are 
gaining momentum worldwide. This particularly holds true 
for the cosmetics sector, where a full animal testing ban has 
been imposed by European legislation a number of years ago 
(EU 2009). In this respect, tiered animal-free approaches 
for the safety evaluation of cosmetic ingredients, driven by 
exposure and mechanistic information, have been developed 
(Dent et al. 2018; Desprez et al. 2018). This has stimulated 
other industries also to explore the application of such strate-
gies for chemical risk assessment more generally, thus com-
plying with the 3Rs principle (i.e. replacement, reduction 
and refinement of animal experimentation) (Russell and 
Burch 1959). Among these is the food additive area, which 
still largely relies on testing in animal models for hazard 
identification purposes. In this context, the task force of 
“New approaches to chemical risk assessment for foods and 
food ingredients” at the International Life Sciences Institute 
(ILSI) Europe intensively monitors and evaluates such non-
animal strategies for implementation in current chemical risk 
assessment practice. In 2017, this ILSI Europe task force 
established an expert group to specifically explore the use 
of AOPs in the safety evaluation of food additives. One of 
the key activities of this expert group was the organization 
of a workshop aimed at triggering an in-depth discussion on 
potentials and challenges related to the application of AOPs 
in the food industry. This workshop was organized on 26–27 
February 2019 in Brussels, Belgium and gathered approxi-
mately 30 experts with an academic, industrial or regulatory 
background. The present manuscript describes the major 
outcomes and recommendations from this workshop, and 
as such is a follow-up of a study of the ILSI expert group 
that characterized the coverage of critical effects relevant 
in the safety evaluation of food additives by AOPs (Kramer 
et al. 2019). The results of the workshop are described fol-
lowed by some critical considerations and perspectives from 
the members of the expert group on the use of AOPs in the 
safety evaluation of food additives.
Outcome of the workshop
ILSI Europe’s workshop on the use of AOPs in the safety 
evaluation of food additives comprised a combination of 
expert lectures and break-out group discussions. Expert 
lectures covered AOP topics from a number of different 
perspectives, including case studies from the regulatory, 
cosmetics and pesticide sectors. In pesticide safety, the 
United States Environmental Protection Agency (US 
EPA) uses AOPs to help establish common mechanism 
groups for cumulative risk assessment, and the European 
Food Safety Authority (EFSA) is using AOPs to under-
stand mechanisms of toxicity as part of safety evaluation. 
Regulatory changes in the cosmetics industry have led the 
way in forcing the hand of regulators and toxicologists to 
champion new approaches, with AOPs seeing use in haz-
ard identification/characterization to help the identification 
of the critical effect on which to base the determination of 
the point-of-departure. These examples show the value of 
good data, AOP development and regulatory acceptance 
in the deployment of new approaches to safety evaluation.
During the break-out sessions, the workshop partici-
pants were asked to consider several questions (Table 1). 
The workshop participants agreed that AOP development 
and usage is still predominantly an academic exercise, as a 
means to organize molecular mechanisms in a toxicologi-
cally relevant pathway. However, it was emphasized that 
AOPs share many conceptual similarities with modes-of-
action, the application of which in regulatory risk assess-
ment is well established. Hence, some of the lessons 
learned will be of value in the introduction of AOPs of 
this purpose. It was also noted that the concept of AOPs 
is already well ingrained into the language of environmen-
tal risk assessment and the safety evaluation of cosmetic 
ingredients. In both cases, AOPs are applied as part of a 
tiered assessment approach and a means of prioritizing 
tests.
The workshop participants classified the use of AOPs in 
non-food sectors as either part of a top-down or bottom-up 
Table 1  Questions covered by the attendees of the ILSI Europe workshop “The use of AOPs for the safety evaluation of food additives” organ-
ized on 26–27 February 2019 in Brussels-Belgium
How are you currently using the AOP framework or how do you envision to use it in the future in your field of work?
(How) could the food industry similarly apply the AOP concept to improve food safety assessment?
At what point in the hazard identification of a food additive do you see a potential to use the AOP concept?
Can the use of AOPs contribute to replacing animal studies in the hazard assessment of food additives?
How would you apply the AOP framework for the different types of food safety assessment from screening to regulation?
What do AOPs need to contain to be useful in the safety assessment of food additives?
What are the shortcomings and major gaps in knowledge hampering the application of AOPs in the safety assessment of food additives?
What is needed to address these gaps?
How can risk assessment methodologies be adapted to best use AOPs?
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approach. The former approach entails using AOPs to 
design in  vitro test batteries for testing (new) chemi-
cal entities for their ability to perturb the pathways and 
provide evidence for a likelihood of a particular adverse 
health outcome to occur. An example of such an approach 
is the use of the skin sensitization AOP for safety testing 
of cosmetic ingredients. In vitro tests, including the direct 
peptide reactivity, anti-oxidant/electrophile response ele-
ment nuclear erythroid 2-related factor 2 and human cell 
line activation test assays, cover specific key events (KEs) 
within this AOP, for which specific test guidelines at the 
Organization for Economic Cooperation and Develop-
ment (OECD) have been developed. These assays allow to 
assess the sensitizing potential of chemicals by integrating 
the results of each assay in a weight-of-evidence approach. 
Such an approach is also used to sort chemicals according 
to their perturbation potential of KEs and use the assay 
results to justify read-across. In other words, AOPs are a 
means of performing read-across by toxicological mecha-
nism. In doing so, it allows for a strategy to assess what 
tests to perform for each individual chemical.
The bottom-up approach is increasingly applied in aca-
demic and industrial settings. It entails using AOPs to 
discern and classify molecular mechanisms of toxicity. In 
this context, safety evaluations move away from assessing 
whether exposure to a particular chemical is associated 
with a particular toxic endpoint, such as hepatotoxicity, but 
rather how to integrate various pieces of information, from 
bioinformatics, biomonitoring data to animal test results, 
into an integrated understanding of how multiple stressors 
affect the overall health of specific populations. Examples 
of these can be seen in ecotoxicology, including the devel-
opment of AOPs leading to chronic fish toxicity focused on 
directly experimentally measurable KEs shared by multiple 
pathways, in casu impaired swimbladder inflation (Ville-
neuve et al. 2014). AOPs conveniently provide a mechanis-
tic underpinning that is pivotal in understating whether the 
adverse outcomes observed with particular chemical expo-
sures in animal toxicity studies are of relevance to humans 
(Bal-Price and Meek 2017; Jeong and Choi 2017).
The workshop participants agreed that AOPs could be 
used in a similar way in the food industry, as similar prin-
ciples of evaluation apply. Both the bottom-up and top-
down approaches are considered to be useful for perform-
ing safety evaluation of food additives. The use of AOPs 
in the safety evaluation process is expected to occur at the 
hazard identification stage, where in vitro and in silico 
assays flag possible perturbations of KEs of known AOPs. 
This, in turn, may help in devising a test strategy for haz-
ard characterization (i.e. dose–response assessment) of 
new chemical entities from which points-of-departures 
are derived. AOPs can also be used to identify mecha-
nisms of toxicity associated with adverse outcomes found 
in toxicity tests, and thus help determine the relevance of 
the toxic effect to humans. In addition, information from 
AOP perturbations, such as from screenings, allows for 
incorporation of additional endpoints, such as induction of 
biotransformation enzymes, to explain liver effects (Kang 
et al. 2018; Nepelska et al. 2017). For example, when it 
is known that the tumorigenesis of a chemical in rodents 
is related to peroxisome proliferator-activated receptor 
alpha activation, using these data for risk assessment is 
questionable, since the pathway is not relevant in humans 
(Corton et al. 2018). AOPs allow for a better understand-
ing of species specificity of adverse health effects and thus 
allow for the selection of appropriate animal species for 
testing (i.e. refinement). AOPs also allow for carrying out 
mechanistically-based read-across approaches and provide 
arguments for performing limited targeted animal testing 
or, ideally, avoiding them. In sectors where in vivo toxicity 
data are still a regulatory requirement, such as the phar-
maceutical industry, the complete replacement of animal 
testing would first require appropriate changes in policy 
and legislation. Nevertheless, with the projected gain in 
efficiency in testing provided by the use of AOPs, animal 
testing is likely to be reduced and refined.
A specific challenge in considering the use of AOPs in 
the safety evaluation of food additives is the lack of data to 
develop food-industry relevant AOPs. While the pharma-
ceutical industry has ample clinical studies to relate specific 
human health outcomes to in silico, in vitro and preclinical 
data, such data are often lacking for food additives. AOPs 
relevant to food additives are likely to vary from the path-
ways common in other industries, such as for endpoints-like 
gastrointestinal tract irritation, an area where many of the 
molecular mechanisms are currently unknown. An AOP to 
assist in understanding this would be of enormous value to 
the food industry. As analyzed by Kramer et al. (2019) as 
part of the ILSI Europe expert group activities, the adverse 
outcomes associated with food additives include a number 
of non-specific, late-onset and/or local effects, such as body 
weight changes, for which no AOPs have been developed. 
Particularly molecular initiating events (MIEs) and early 
KEs are currently insufficiently identified, and chemicals 
will likely perturb numerous MIEs simultaneously when 
point-of-departure values are high. Given the non-specific 
nature of the adverse outcomes, it is also essential that KEs 
and measurable intermediate effects associated with mul-
tiple pathways are identified. By identifying these “super-
hubs”, directed in vitro and in silico testing strategies could 
be applied to inform multiple AOPs rapidly. Moreover, it 
is essential to quantify AOPs and consider networks when 
using them for the safety evaluation of food additives. 
Changes in biomarkers of a plethora of KEs in bioassays 
could be quantitatively associated with high human expo-
sures leading to multiple adverse outcomes. This requires the 
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integration of toxicokinetic processes, modulating factors 
and feedback loops in AOPs.
A final consideration from the workshop participants was 
the desire for an overarching AOP strategy on an interna-
tional level integrating expert researchers, toxicologists and 
regulators. This could help to define the criteria required to 
ensure a food additive is safe and guide AOP development 
in both a qualitative and quantitative respect. Construction 
of AOPs is a challenging and time-consuming task. While 
many biological mechanisms are currently well understood, 
AOPs simply have not been constructed for these yet. Medi-
cal doctors have much of the required knowledge to assist in 
AOP development, thus AOP developers need to get them 
on board. Ultimately, an AOP strategy for food additive 
safety must convince those in the industry and regulators 
of its value through reduced cost, but also must be scien-
tifically sound and human-relevant. Incorporation of more 
in vitro and in silico methods can certainly be faster than 
current methods as well, helping the industry to keep up with 
demands (Ehrlich et al. 2015).
In conclusion of the workshop, several key aspects of 
AOP development and deployment require further consid-
eration to be used in food additive safety evaluation, and 
perhaps more generally. For AOPs to be used in food addi-
tive safety evaluation, there will need to be a focus on AOPs 
relevant to those chemicals, both in the case of optimizing 
existing AOPs to make them fit-for-purpose and for develop-
ing new AOPs for adverse health effects that could be rel-
evant for food additives, such as food allergies/intolerances 
and gastrointestinal tract irritation. These AOPs can be com-
bined with others to identify “superhub” KEs that can allow 
for the evaluation of multiple pathways at once, improv-
ing the efficiency of testing. To aid in the development of 
these AOPs, a better level of mechanistic understanding is 
required and one source of this knowledge could be through 
clinicians. EFSA guidance and further case studies are 
needed to explore the use of AOPs in the food sector, and in 
the future, these AOPs need to be quantitative to provide the 
necessary information for food safety assessment. Finally, 
the ILSI Europe expert groups on AOPs and ToxCast data 
should be linked to establish overlap and as a foundation for 
the further developments outlined above.
Critical considerations and perspectives
The outcome of the workshop clearly highlighted the impor-
tance of AOPs and the possibilities for their use in the pro-
cess of safety evaluation of food additives. The workshop 
indicated that the use of AOPs in the safety evaluation 
process is at the moment most likely at the hazard iden-
tification stage. Thus, AOPs may help in defining critical 
effects, target organs and relevance of the adverse outcome 
for human risk assessment. This could be particularly useful 
considering that often the adverse effects seen at high-dose 
animal studies are of low relevance in the context of much 
lower human exposure levels or when the mechanism-of-
action is species-specific. The use of exposure informa-
tion is a key element to understand the correlation between 
in vitro concentrations and in vivo doses, and consequently 
the relevance to human exposure scenarios. Moreover, the 
development and use of human-relevant AOPs could aid the 
shift to a new paradigm for safety evaluation that does not 
necessarily rely on the extrapolation and/or on the predic-
tion of animal data, but rather makes use of human-relevant 
mechanistic information, such as those derived from in vitro 
human cell-based assays and/or in silico approaches.
AOPs may also support the selection of adequate in vitro 
assays to detect KEs that are relevant for a specific mech-
anism-of-action. Furthermore, AOPs may facilitate read-
across and provide support for the determination of relative 
potencies of related chemicals in a group based on a similar 
mode-of-action.
Inclusion of AOPs in a testing strategy for the hazard 
characterization (i.e. dose–response assessment) of new 
chemical entities to define points-of-departure appears less 
straightforward. In this context, the US EPA has recently 
published a risk-based tiered testing framework that com-
bines computational modelling, high-throughput assays 
and AOPs to estimate points-of-departure for chemical 
safety assessment (Thomas et al. 2019). Points-of depar-
ture for risk assessment include, for example, no-observed-
adverse-effect levels or benchmark-dose-lower-confidence 
limits usually derived from dose–response data from api-
cal toxic endpoints. The use of the molecular/cellular end-
points for risk assessment, such as those reflecting KEs in 
an AOP, carries a number of challenges. First, it still needs 
to be established whether and at what level the perturbation 
seen in KEs is relevant for the prediction of the apical toxic 
endpoint (i.e. the adverse outcome). This would require the 
development and use of quantitative, not only qualitative, 
AOPs for systemic toxic endpoints, as described recently 
by Perkins et al. (2019), Zgheib et al. (2019), and Battistoni 
et al. (2019). Moreover, points-of-departure derived from 
in vitro bioassays reflecting KEs in an AOP cannot directly 
be converted into health-based reference values. Indeed, this 
requires translation of the in vitro concentration–response 
data to in vivo dose–response data taking kinetics into 
account. Although the workshop pointed to the importance 
of including kinetics in AOPs, this is presently limited to 
describing, for example, bioactivation as one of the KEs. 
The incorporation of exposure and toxicokinetic information 
into the AOP framework is one of the main challenges when 
considering the use of mechanistic data to derive a point-of-
departure. This may best be achieved by combining AOPs 
with physiologically-based kinetic (PBK) models. Today, 
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many examples, some of those involving food chemicals, 
have been provided showing that the use PBK model-based 
reverse dosimetry for quantitative in vitro-to-in vivo extrapo-
lation (QIVIVE) enables definition of points-of-departure 
for risk assessment (Levorato et al. 2019; Louisse et al. 
2017). Thus far, this concept has not been used for AOPs 
specifically, although it could play a role in supporting the 
choice and relevance of the in vitro bioassay used to identify 
critical molecular endpoints. Another approach that is gain-
ing popularity is the comparison of high-throughput bioac-
tivity data, which could be representative for a specific MIE, 
with PBK-predicted human plasma concentrations (Dent 
et al. 2019; Wetmore et al. 2015). This type of approach is 
particularly promising as it is entirely focused on the assess-
ment of human safety rather than trying to correlate and 
extrapolate animal toxicity data to the human situation.
The use of AOPs may also become relevant when there 
is a need for extending a validated QIVIVE-based predic-
tion for a chemical for which toxicological data are lack-
ing, but which are available for related chemicals. In such 
cases, AOPs may support that the chemicals act similarly, 
so that the QIVIVE approach proven valid for one chemical 
in the group may be used for related chemicals. Obviously, 
potential differences in kinetics should then still be taken 
into account.
The results of the workshop also clearly argued that lack 
of mechanistic knowledge may result in inadequate safety 
assessment. This is not a new observation, since information 
on mode-of-action often has been, and still is, essential in 
risk assessment, as can best be illustrated by some examples. 
A first example is the endpoint of carcinogenicity and the 
question of whether the underlying mode-of-action involves 
genotoxicity or not. Depending on the mode-of-action, the 
risk assessment is performed differently. For instance, given 
that no safe level of exposure can be anticipated for geno-
toxic carcinogens, no acceptable daily intake value can be 
established for these compounds, which are not allowed for 
use as food additives (EFSA 2005). Other examples where 
mode-of-action considerations were already an integral part 
of risk assessment before introduction of the AOP concept 
are in determining the relevance, or lack thereof, to humans 
of alpha 2u-globulin-related kidney toxicity observed only 
in male rats and not in female rats or humans (Doi et al. 
2007), and rodent thyroid tumors following induction of 
thyroid hormone glucuronidation (Boobis et al. 2016). This 
also holds for the example presented during the workshop 
of hepatic tumorigenesis in rodents via peroxisome prolifer-
ator-activated receptor alpha activation, which is a pathway 
not relevant in humans (Corton et al. 2018). The advantage 
of the AOP initiative is in the international activity being 
coordinated by the OECD to provide a global repository 
of information and an AOP-based assessment strategy for 
chemicals.
A bottleneck highlighted by the workshop participants 
for the application of AOPs in the safety assessment of food 
additives might be the availability of relevant data to develop 
AOPs for these compounds, as opposed to, for example, 
drugs or pesticides. There may be several reasons underly-
ing this situation, which may not be easily resolved. First, 
as shown by the study of Kramer et al. (2019), character-
izing the coverage of critical effects relevant in the safety 
evaluation of food additives by AOPs, food additives are not 
designed to cause biological effects in humans. For only 22% 
of the food additives currently authorized in the European 
Union, a specific critical adverse effect has been identified 
(Kramer et al. 2019). This implies that how AOPs can be 
used as part of the standard battery of guideline require-
ments for safety testing of food additives needs detailed and 
careful assessment, and their use should be considered on 
a case-by-case basis. A possible application for the evalu-
ation of new food additives, based on the framework pro-
posed by the US EPA (Thomas et al. 2019), could be to run 
high-throughput screening assays across different cell lines 
targeting MIEs that lead to adverse outcomes that are com-
monly used for regulatory purposes. Based on the results, 
more specific tests could be performed to provide insight 
into the mode-of-action of the chemical. Another considera-
tion is that, in contrast to drugs, food additives are not sub-
ject to risk–benefit consideration. Food additives will only 
be accepted when they do not pose a safety concern to the 
health of the consumers. This implies that including clinical 
input in the development of AOPs for food additives, as sug-
gested during the workshop, may only be of use for certain 
endpoints. This may include, for example, allergy-related 
effects, since at present, allergy is an endpoint not consid-
ered suitable for defining health-based safety values for food 
additives. Allergens are rather regulated via adequate label-
ling, so that individuals who are allergic to a particular food 
additive can avoid exposure. It could be foreseen that for 
these types of adverse effects, the AOPs and model systems 
used for skin sensitization may prove to be of use.
In addition, the analysis of Kramer et al. (2019) revealed 
that the toxicological endpoints used for the safety assess-
ment of food additives could be linked to a number of dif-
ferent AOPs. Therefore, understanding the specific mech-
anism-of-action leading to an adverse effect and, in case 
of chemicals acting via multiple mechanisms-of-action, the 
integration of information covered by different AOPs would 
be crucial to inform the risk assessment.
Finally, it is of interest to evaluate to what extent the 
workshop answered the questions put forward. The work-
shop provided views and perspectives on how the food 
industry could apply the AOP concept to improve the quality 
of their scientific dossiers, taking into account information 
on the mode-of-action to support relevance of test models 
chosen and/or adverse effects observed in animal studies. 
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The workshop participants also concluded that AOPs may 
be especially of use in the hazard identification of a food 
additive identifying the relevance of the target organ/sys-
tem, model organism or type of adverse effect for humans. 
Furthermore, the workshop participants acknowledged that 
the use of AOPs can contribute to reducing and refining 
animal studies in the hazard identification of food additives. 
Indeed, the use of AOPs could facilitate the shift to a new 
paradigm of safety assessment that makes use of a human-
based mechanistic approach rather than relying on the pre-
diction and/or extrapolation of animal toxicity data. More 
research is needed to understand how AOPs could assist in 
the definition of a dose–response curve in the process of haz-
ard characterization, which is essential to establish health-
based guidance values. This would require development of 
quantitative AOPs that describe concentration–response 
curves for the rate-limiting step for induction of the adverse 
effect, which may subsequently be translated into in vivo 
dose–response curves using PBK models.
The workshop also indicated how regulators are cur-
rently using the AOP framework or envision its use in the 
future, since AOPs share many conceptual similarities with 
modes-of-action. In the future, use of AOPs for read-across 
from data-rich compounds to data-poor compounds is an 
opportunity, although read-across is currently very scarcely 
implemented in the safety evaluation of food additives. Note-
worthy, for food flavors, which represent another category 
of food additives, use of read-across is an essential part of 
the regulatory framework (Cohen et al. 2018; EFSA 2010), 
so that a future role for AOPs in this field may become an 
option.
The question on what shortcomings and major gaps 
in knowledge are hampering the application of AOPs in 
the safety assessment of food additives was answered by 
pointing to the lack of AOPs for certain endpoints, such as 
gastrointestinal tract irritation, as well as for a number of 
non-specific, late-onset and/or local effects, including body 
weight changes, for which no AOPs have been developed.
The question on what is needed to address these gaps 
suggested the role of clinicians, although, as outlined above, 
effects of food additives in the clinic may be absent or per-
haps limited to allergies/intolerances, which is an endpoint 
thus far not used as the basis for health-based guidance val-
ues for food additives.
The workshop was unable to provide an answer to the 
question of how one would apply the AOP framework 
across all the different types of food safety assessments, 
from screening to regulation. Considering what informa-
tion is needed in the safety assessment of food additives, the 
necessity to integrate AOPs with knowledge of the kinetics 
of test chemicals was noted. Thus, integrating PBK models 
into the AOP concept may be an essential way forward for 
comprehensive non animal-based risk assessments.
The final question on how risk assessment methodolo-
gies can be adapted to best use AOPs can be related to the 
fact that current risk assessment methodologies already con-
sider modes-of-action. A wider role for AOPs in future risk 
assessment may probably best focus on providing support 
for read-across. If so, AOPs can play a role in providing 
mechanistic support for alternative testing strategies, includ-
ing QIVIVE and read-across.
So far, the use of AOPs in risk assessment has been 
applied successfully for the endpoint of skin sensitization, 
which has led to its regulatory acceptance in the cosmetics 
sector. Although a number of challenges need to be tackled 
to be able to apply the AOP framework in other sectors, 
including the food industry, considerable research effort has 
been made in the last years in that direction. It appears clear 
that the full realization of the AOP potential will signifi-
cantly impact the current risk assessment paradigm, lead-
ing eventually to a human-focused rather than animal-based 
approach.
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